NCT03245918View on ClinicalTrials.gov

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

January 5, 2018

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Aprepitant Capsule 125 MG

Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period

DRUG

Aprepitant oral suspension 20 mg/mL

Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period

Trial Locations (1)

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT03245918 - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter